Interim Co-President and Co-Chief Executive Officer, Executive Vice President, Chief Financial Officer
Graham Miao joined Delcath as Executive Vice President and Chief Financial Officer in September 2011, and was appointed interim Co-President and Co-CEO by the Board of Directors in September, 2013. In his current position, Dr. Miao has responsibility for strategy, corporate and business development, all aspects of financial operations and capital raise, investor relations, legal, human resources and information technology. He previously served as Chief of Staff, Global CFO Organization and member of Financial Leadership Team at Dun & Bradstreet Corporation since 2009 where he worked with CFO and senior management team to drive corporate strategic initiatives and Board deliverables. Previously, Dr. Miao was Executive Vice President & CFO of Pagoda Pharmaceuticals, a Shanghai-based specialty pharmaceuticals and medical device company. Prior to joining Pagoda, Dr. Miao was Vice President of Strategic Planning & Financial Analysis at Symrise Inc., a German supplier of flavoring and fragrance products. In this role Dr. Miao served as division-CFO responsible for driving profitable growth of a $700 million business line. Dr. Miao was also Senior Director for Global Primary Care and Global Medical Affairs at Schering-Plough Corporation, serving as the division-CFO for the company’s $3 billion primary care pharmaceuticals franchise. Prior to his time at Schering-Plough, Dr. Miao was at Pharmacia Corporation, serving as Director-Head of Finance for Pharmacia’s $1.3 billion Global Oncology franchise where he led finance teams across marketing, sales, medical affairs, business development, and mergers & acquisitions. Earlier in his career, Dr. Miao worked as a biotechnology analyst at J.P. Morgan and Company. Dr. Miao earned an M.B.A. in finance and a Ph.D. in biological sciences from Columbia University, an M.S. in molecular biology from Arizona State University, and a B.S. in biochemistry from Fudan University in Shanghai, China.